Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Global Payments
GPN
|
+$308M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$76.7M |
| 3 |
American Homes 4 Rent
AMH
|
+$69.4M |
| 4 |
Equinix
EQIX
|
+$51.2M |
| 5 |
Americold
COLD
|
+$48.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NiSource
NI
|
+$77.7M |
| 2 |
Linde
LIN
|
+$71M |
| 3 |
DTE Energy
DTE
|
+$57.1M |
| 4 |
Freeport-McMoran
FCX
|
+$51.7M |
| 5 |
FedEx
FDX
|
+$44.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 11.05% |
| 2 | Technology | 9.71% |
| 3 | Healthcare | 9.12% |
| 4 | Real Estate | 6.85% |
| 5 | Utilities | 6.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Lennar Class B
LEN.B
$20.6B
| $140K | ﹤0.01% |
+1,302
| New | +$122K |
|
1727
Pulmonx
LUNG
$97.1M
| $140K | ﹤0.01% |
+10,689
| New | +$131K |
|
|
ENFN
1728
DELISTED
Enfusion, Inc.
ENFN
| $139K | ﹤0.01% |
12,357
-71,793
| -85% | -$637K |
|
1729
Compañía de Minas Buenaventura
BVN
$9.01B
| $138K | ﹤0.01% |
18,718
-1,249
| -6% | -$9.21K |
|
1730
TransAlta
TAC
$3.86B
| $138K | ﹤0.01% |
+14,796
| New | +$139K |
|
1731
Teva Pharmaceuticals
TEVA
$43.5B
| $138K | ﹤0.01% |
18,265
-331,735
| -95% | -$2.69M |
|
1732
Alamos Gold
AGI
$15.8B
| $136K | ﹤0.01% |
+11,401
| New | +$145K |
|
1733
Future Fuel
FF
$244M
| $135K | ﹤0.01% |
+15,300
| New | +$128K |
|
|
SKYT
1734
DELISTED
SkyWater Technology
SKYT
| $133K | ﹤0.01% |
+14,082
| New | +$135K |
|
1735
Bausch Health
BHC
$2.41B
| $130K | ﹤0.01% |
+16,277
| New | +$120K |
|
1736
Energy Vault
NRGV
$691M
| $129K | ﹤0.01% |
+47,362
| New | +$99.7K |
|
|
RPC
1737
Ridgepost Capital
RPC
$966M
| $128K | ﹤0.01% |
11,324
-648
| -5% | -$6.88K |
|
1738
Solid Power
SLDP
$541M
| $127K | ﹤0.01% |
50,047
+9,845
| +24% | +$22.7K |
|
|
CFB
1739
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $125K | ﹤0.01% |
+12,511
| New | +$129K |
|
|
ME
1740
DELISTED
23andMe Holding Co
ME
| $125K | ﹤0.01% |
+3,574
| New | +$142K |
|
1741
Santander
BSBR
$43B
| $123K | ﹤0.01% |
19,320
-85,810
| -82% | -$501K |
|
|
INZY
1742
DELISTED
Inozyme Pharma
INZY
| $123K | ﹤0.01% |
+22,081
| New | +$131K |
|
1743
VTEX
VTEX
$603M
| $123K | ﹤0.01% |
+25,542
| New | +$101K |
|
1744
Blink Charging
BLNK
$86.2M
| $119K | ﹤0.01% |
19,825
-9,676
| -33% | -$67K |
|
1745
Enviri
NVRI
$582M
| $118K | ﹤0.01% |
+11,969
| New | +$98.6K |
|
1746
Cipher Digital
CIFR
$6.55B
| $115K | ﹤0.01% |
+40,239
| New | +$99.1K |
|
1747
Fate Therapeutics
FATE
$279M
| $115K | ﹤0.01% |
24,251
-72,984
| -75% | -$403K |
|
1748
ASE Group
ASX
$95.1B
| $114K | ﹤0.01% |
14,649
-132,022
| -90% | -$1.02M |
|
1749
Microvision
MVIS
$50.8M
| $107K | ﹤0.01% |
1,564
+717
| +85% | +$37.6K |
|
1750
Getty Images
GETY
$111M
| $101K | ﹤0.01% |
+20,695
| New | +$119K |
|
Similar funds
Michael Gelband's Q2 2023 Portfolio in Review
As of Q2 2023, Michael Gelband held 2,377 positions worth $12.3B, up 1.9% from $12.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Michael Gelband's Q2 2023 filing shows 669 new, 496 increased, 623 reduced and 582 closed positions. Its largest new stake was Pioneer Natural Resource Co.: 364,360 shares worth $75.5M. The largest sale was NiSource, an estimated $77.7M.
By sector, the portfolio is most concentrated in Industrials at 11% of assets, up from 11% a quarter earlier, followed by Technology and Healthcare.
- Michael Gelband's largest Q2 2023 buy was Pioneer Natural Resource Co.: 364,360 shares worth $75.5M.
- Michael Gelband added most to Global Payments in Q2 2023, an estimated $308M increase.
- Michael Gelband's biggest Q2 2023 reduction was NiSource, cutting an estimated $77.7M.
- Michael Gelband fully exited L3Harris in Q2 2023, selling an estimated $44.7M.
- Michael Gelband's ten largest holdings make up 25% of its $12.3B portfolio in Q2 2023.
- Michael Gelband opened 669 new positions and closed 582 in Q2 2023.
- Michael Gelband's portfolio value rose 1.9% quarter-over-quarter to $12.3B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.